Dot matrix laser combined with Beifuxin for the treatment of chronic wounds

Clinical Study on the Combination of Ultra-Pulsed Carbon Dioxide Fractional Laser and Recombinant Bovine Basic Fibroblast Growth Factor Gel in the Treatment of Chronic Wounds

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2600122270

Enrollment

Unknown

Registered

2026-04-10

Start date

2026-04-10

Completion date

Unknown

Last updated

2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic wounds

Interventions

Exposure group: carbon dioxide laser+rb-bFGF Gel combined treatment group

:None

Non exposure group: rb-bFGF Gel monotherapy group:None

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Age range: 18-85 years old; 2. The duration of the wound is >= 4 weeks; 3. The wound area is 2-30cm ²; 4. The basic disease is stable (blood sugar of diabetes patients<10mmol/L, blood pressure of hypertension patients<160/100mmHg); 5. The patient provides informed consent and signs the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients with severe dysfunction of important organs such as heart, liver, and kidney; 2. Patients with coagulation dysfunction; 3. Patients with wounds combined with malignant tumors; 4. Those who are allergic to laser treatment or bevacizumab; 5. Pregnant and lactating women.

Design outcomes

Primary

Measure	Time frame
wound healing rate;Wound healing time;	—

Countries

China

Contacts

Public ContactSONG MENGJIE

Yuebei People’s Hospital

272210284@qq.com+86 751 6913337

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026